Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer to invest billions in plants in Europe

By Brian Buntz | December 2, 2022

Pfizer logoPharma giant Pfizer (NYSE:PFE) plans to spend more than $2.5 billion in facilities in Belgium and Ireland as it looks to diversify its product portfolio, according to Reuters.

In 2021, Pfizer generated $36.9 billion in sales from the Comirnaty COVID-19 vaccine. The company projects its COVID-19 vaccine to rake in $34 billion in 2022, but COVID-related sales will likely steadily fall in the coming years.

For now, the company is flush with cash. Expecting to top $100 billion in revenue in 2022, the company generated $81.2 billion last year. The company has used the funds to acquire a string of companies, including Reviral, Arena Pharmaceuticals, Biohaven Pharmaceuticals and Global Blood Therapeutics.

Pfizer will invest €1.2 billion ($1.26 billion) to upgrade and invest in a plant in Puurs, Belgium. It will spend the same sum on upgrading a plant in Dublin.

The Puurs site and a facility in Kalamazoo are pivotal sites for producing the COVID-19 vaccine.

Pfizer anticipates beginning construction at the Dublin site in 2024 and finalizing the project in 2027.

Pfizer faces patent cliffs in the coming years for several drugs, including

Eliquis (which it jointly developed with Bristol Myers Squibb), Ibrance and Xeljanz.

In its Q3 earnings, the company acknowledged that it expected a loss of roughly $17 billion between 2025 to 2030.

“We believe we not only can overcome these expected declines but also can potentially generate strong growth through the end of the decade,” said the company’s CEO, Dr. Albert Bourla.

The company aims to launch up to 19 new drugs in the next 18 months—promising pipeline drugs, including its investigational RSV vaccine and Prevnar 20 pneumococcal vaccine. The company believes that two-thirds of the 19 drug candidates have the potential to be blockbusters.

Pfizer anticipates hiring between 400 to 500 new workers to help staff its expanded plant in Ireland, which specializes in creating material for biologics and vaccines.

The investment in the Puurs facility will increase its capacity for packaging, cold storage and drug substance manufacturing. In addition, Pfizer aims to recruit 250 new workers for the site, which now employs about 4,500 workers.

Pfizer also aims to make similar investments in plants in Kalamazoo, Michigan; Rocky Mount, North Carolina and McPherson, Kansas.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE